Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma Group Limited has reported a change to its issued capital following the lapse of 268,866 performance rights. These rights, trading under the ASX code MYXAN, ceased on 1 May 2026 after conditions attached to the awards were not met or became incapable of being satisfied.
The lapse of the performance rights reduces the company’s pool of potential equity-based remuneration and slightly lowers potential future dilution for existing shareholders. This adjustment reflects the non-fulfilment of specific performance or service hurdles and provides the market with an updated view of Mayne Pharma’s outstanding securities structure.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian pharmaceutical company listed on the ASX under the code MYX. The company operates in the healthcare and life sciences sector, focusing on the development, manufacture, and distribution of specialty and generic medicines across various therapeutic areas.
YTD Price Performance: -10.61%
Average Trading Volume: 480,456
Technical Sentiment Signal: Sell
Current Market Cap: A$225.9M
Learn more about MYX stock on TipRanks’ Stock Analysis page.